EGFR-directed therapies in squamous cell carcinoma of the head and neckEGFR-directed therapies in squamous cell carcinoma of the head and neck
Faculty of Medicine and Health Sciences
Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO)
London :Future Medicine, 2012[*]2012
EGFR inhibitors in cancer treatment / Ciardiello, Fortunato [edit.]
University of Antwerp
The EGF receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). EGFR-directed therapies include monoclonal antibodies and tyrosine kinase inhibitors. The addition of the monoclonal antibody cetuximab to irradiation improves the outcome in locoregionally advanced SCCHN. The addition of an EGFR-directed monoclonal antibody, particularly cetuximab, to a platinum-based chemotherapy improves the outcome in recurrent/metastatic SCCHN. EGFR-directed monoclonal antibodies have activity in platinum-refractory SCCHN, although the benefit might be less than expected. The activity of EGFR-directed tyrosine kinase inhibitors in SCCHN so far has been disappointing.